MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.450
+0.030
+1.24%
After Hours: 2.440 -0.01 -0.41% 17:45 01/15 EST
OPEN
2.450
PREV CLOSE
2.420
HIGH
2.520
LOW
2.380
VOLUME
3.88M
TURNOVER
--
52 WEEK HIGH
4.670
52 WEEK LOW
1.080
MARKET CAP
415.95M
P/E (TTM)
-2.6604
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and the grant ...
Business Wire · 01/07 21:05
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and the grant of 43,125 restricted stock units (RSUs) to five new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $2.20 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on January 4, 2021. The stock options and RSUs that were granted to the five new employees will vest at a rate of twenty-five percent (25%) on the one year anniversary of the employee's date of hire, with the remaining shares vesting quarterly over the next three (3) years in equal quarterly amounts, provided the employees continue to serve as employees of or other service providers to Verastem Oncology on each such vesting date.
BusinessWire · 01/07 18:05
Verastem Oncology appoints chief medical officer
Verastem (VSTM) appoints of industry veteran Frank Neumann, M.D., Ph.D., as chief medical officer to oversee the company’s clinical and regulatory strategy and medical affairs team.Appointment reflects progress of the company's RAS
Seekingalpha · 01/06 14:33
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical ...
Business Wire · 01/06 14:13
Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
--Verastem Recently Initiated Registration-Directed Trials with VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer and KRAS Mutant Non-Small Cell Lung Cancer
BusinessWire · 01/06 11:13
Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conf...
Business Wire · 01/05 12:00
Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference
Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.
BusinessWire · 01/05 09:00
Who Has Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...
Simply Wall St. · 12/29/2020 13:02
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VSTM. Analyze the recent business situations of Verastem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VSTM stock price target is 3.833 with a high estimate of 5.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 198
Institutional Holdings: 68.25M
% Owned: 40.20%
Shares Outstanding: 169.77M
TypeInstitutionsShares
Increased
31
8.54M
New
35
-9.62M
Decreased
41
6.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
President/Chief Operating Officer
Daniel Paterson
Chief Executive Officer/Director
Brian Stuglik
Chief Financial Officer
Robert Gagnon
Lead Director/Independent Director
Michael Kauffman
Independent Director
Timothy Barberich
Independent Director
Gina Consylman
Independent Director
Alison Lawton
Independent Director
Eric Rowinsky
Independent Director
Bruce Wendel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.